Press Release
Toronto, Canada, January 22, 2024 — Alpha Cancer Technologies (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that Dr. Igor Sherman, President & CEO, will present on February 26, 2024 at the 3rd Annual Next-Generation Conjugates Summit. The conference is taking place February 26-28, 2024 in Boston. For more information, please visit this link